Perez, J.R. et al. 2020. Posterior Reversible Encephalopathy Syndrome (PRES) in a Patient Treated with a Novel Combination Treatment with Anti PDL1 Antibody (Durvalumab) and VEGFR2 Antibody (Ramucirumab). Archives of Clinical and Medical Case Reports. 4, 1 (Jan. 2020), 8–14.